Researchers link gut microbiome to rheumatoid arthritis prognosis

by Susan Murphy,Mayo ClinicCredit: Pixabay/CC0 Public DomainA significant indicator of whether a patient with rheumatoid arthritis will improve over the course of disease may lie in part in thei

Updated on: June 01,2024

Researchers link gut microbiome to rheumatoid arthritis prognosis

by Susan Murphy,Mayo ClinicCredit: Pixabay/CC0 Public DomainA significant indicator of whether a patient with rheumatoid arthritis will improve over the course of disease may lie in part in thei

Updated on:June 01,2024

Decline in risk of dementia and heart failure in patients with rheumatoid arthritis

by European Alliance of Associations for RheumatologyCredit: CC0 Public DomainRheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It

Updated on: May 08,2024

Decline in risk of dementia and heart failure in patients with rheumatoid arthritis

by European Alliance of Associations for RheumatologyCredit: CC0 Public DomainRheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It

Updated on:May 08,2024

Major savings possible with app-based osteoarthritis treatment

by Lund UniversityCredit: CC0 Public DomainOsteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in S

Updated on: April 17,2024

Major savings possible with app-based osteoarthritis treatment

by Lund UniversityCredit: CC0 Public DomainOsteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in S

Updated on:April 17,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on: June 17,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on:June 17,2024

A little radiation goes a long way in heating up cold tumors

by Ludwig Cancer ResearchCredit: CC0 Public DomainA Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called "cold&quo

Updated on: April 24,2024

A little radiation goes a long way in heating up cold tumors

by Ludwig Cancer ResearchCredit: CC0 Public DomainA Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called "cold&quo

Updated on:April 24,2024

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

by La Jolla Institute for ImmunologyA multi-layered, virus-specific immune response is important for controlling the virus during the acute phase of the infection and reducing COVID-19 disease se

Updated on: April 24,2024

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

by La Jolla Institute for ImmunologyA multi-layered, virus-specific immune response is important for controlling the virus during the acute phase of the infection and reducing COVID-19 disease se

Updated on:April 24,2024

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on: June 01,2024

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on:June 01,2024

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on: May 05,2024

A bacterial toxin turning cells into swiss cheese

by Kanazawa UniversityResearchers from Kanazawa University developed a novel tool to study how the innate immune system fights bacterial toxins. They purified the pore-forming toxin Monalysin fro

Updated on:May 05,2024

Cell-compressing technique a new path in immunotherapy

by Zach Winn,Massachusetts Institute of TechnologyTo engineer cell functions, SQZ Biotech uses tiny channels on a microfluidic chip to squeeze cells so they can be penetrated by specific molecul

Updated on: April 09,2024

Cell-compressing technique a new path in immunotherapy

by Zach Winn,Massachusetts Institute of TechnologyTo engineer cell functions, SQZ Biotech uses tiny channels on a microfluidic chip to squeeze cells so they can be penetrated by specific molecul

Updated on:April 09,2024

Increased use of partial knee replacement could save the NHS £30 million per year

by University of OxfordCredit: NDORMSNew research from a randomised clinical trial published today inThe Lancetand funded by the National Institute for Health Research (NIHR) shows th

Updated on: March 28,2024

Increased use of partial knee replacement could save the NHS £30 million per year

by University of OxfordCredit: NDORMSNew research from a randomised clinical trial published today inThe Lancetand funded by the National Institute for Health Research (NIHR) shows th

Updated on:March 28,2024

Delivery methods compared for osteoarthritis intervention

First-line intervention for hip or knee osteoarthritis (OA) may reduce pain whether delivered in-person or digitally, according to a study published online Nov. 3 inJAMA Network Open.Therese Jön

Updated on: May 29,2024

Delivery methods compared for osteoarthritis intervention

First-line intervention for hip or knee osteoarthritis (OA) may reduce pain whether delivered in-person or digitally, according to a study published online Nov. 3 inJAMA Network Open.Therese Jön

Updated on:May 29,2024

Lower doses of rheumatoid arthritis drugs may work for some

by Amy Norton, Healthday ReporterStudy found many patients with early stage disease stayed in remission with less medication.(HealthDay)—Some people in the early stages of rheumatoid arthritis may be

Updated on: March 24,2024

Lower doses of rheumatoid arthritis drugs may work for some

by Amy Norton, Healthday ReporterStudy found many patients with early stage disease stayed in remission with less medication.(HealthDay)—Some people in the early stages of rheumatoid arthritis may be

Updated on:March 24,2024